Literature DB >> 20543673

Epinephrine and its use in anaphylaxis: current issues.

Keith J Simons1, F Estelle R Simons.   

Abstract

PURPOSE OF REVIEW: Epinephrine is a life-saving medication in the treatment of anaphylaxis, in which it has multiple beneficial pharmacologic effects. Here, we examine the evidence base for its primary role in the treatment of anaphylaxis episodes in community settings. RECENT
FINDINGS: We review the practical pharmacology of epinephrine in anaphylaxis, its intrinsic limitations, and the pros and cons of different routes of administration. We provide a new perspective on the adverse effects of epinephrine, including its cardiac effects. We describe the evidence base for the use of epinephrine in anaphylaxis. We discuss the role of epinephrine auto-injectors for treatment of anaphylaxis in community settings, including identification of patients who need an auto-injector prescription, current use of auto-injectors, and advances in auto-injector design. We list reasons why physicians fail to prescribe epinephrine auto-injectors for patients with anaphylaxis, and reasons why patients fail to self-inject epinephrine in anaphylaxis. We emphasize the primary role of epinephrine in the context of emergency preparedness for anaphylaxis in the community.
SUMMARY: Epinephrine is the medication of choice in the first-aid treatment of anaphylaxis in the community. For ethical reasons, it is not possible to conduct randomized, placebo-controlled trials of epinephrine in anaphylaxis; however, continued efforts are needed towards improving the evidence base for epinephrine injection in this potentially fatal disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20543673     DOI: 10.1097/ACI.0b013e32833bc670

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  28 in total

1.  How incorrect is the use of adrenaline auto-injectors?

Authors:  Fernando Miguel Gamboa Antiñolo
Journal:  Intern Emerg Med       Date:  2015-08-21       Impact factor: 3.397

2.  Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2.

Authors:  Tolly G Epstein; Gary M Liss; Karen Murphy-Berendts; David I Bernstein
Journal:  Ann Allergy Asthma Immunol       Date:  2011-06-17       Impact factor: 6.347

Review 3. 

Authors:  Constance LeBlanc; Jock Murray; Louis Staple; Bridgette Chan
Journal:  Can Fam Physician       Date:  2019-04       Impact factor: 3.275

Review 4.  Review of emergency preparedness in the office setting: How best to prepare based on your practice and patient demographic characteristics.

Authors:  Constance LeBlanc; Jock Murray; Louis Staple; Bridgette Chan
Journal:  Can Fam Physician       Date:  2019-04       Impact factor: 3.275

Review 5.  [Epidemiology of anaphylaxis].

Authors:  M Worm
Journal:  Hautarzt       Date:  2013-02       Impact factor: 0.751

6.  Long-term effectiveness of online anaphylaxis education for pharmacists.

Authors:  Sandra M Salter; Sandra Vale; Frank M Sanfilippo; Richard Loh; Rhonda M Clifford
Journal:  Am J Pharm Educ       Date:  2014-09-15       Impact factor: 2.047

7.  Sublingual Diffusion of Epinephrine Microcrystals from Rapidly Disintegrating Tablets for the Potential First-Aid Treatment of Anaphylaxis: In Vitro and Ex Vivo Study.

Authors:  Mutasem M Rawas-Qalaji; Shima Werdy; Ousama Rachid; F Estelle R Simons; Keith J Simons
Journal:  AAPS PharmSciTech       Date:  2015-03-04       Impact factor: 3.246

Review 8.  Emerging Therapies in Anaphylaxis: Alternatives to Intramuscular Administration of Epinephrine.

Authors:  Brittany Boswell; Susan A Rudders; Julie C Brown
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

9.  Epinephrine autoinjector refill history in an HMO.

Authors:  Michael S Kaplan; Sandy Y Jung; Matthew L Chiang
Journal:  Curr Allergy Asthma Rep       Date:  2011-02       Impact factor: 4.806

Review 10.  [Emergency treatment and management of anaphylaxis].

Authors:  K Brockow; J Ring
Journal:  Hautarzt       Date:  2013-02       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.